GSKGLAXF 75 3-Year ROIIC % is 38.82 as of Dec. 2025. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.09 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 941 Drug Manufacturers companies, GSK ranks better than 80.02% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
GSK's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 38.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for GSK's 3-Year ROIIC % or its related term are showing as below:
GLAXF's 3-Year ROIIC % is ranked better than 80.02% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.7
vs GLAXF: 38.82
GSK (OTCPK:GLAXF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
GSK 3-Year ROIIC % Related Terms
GSK 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for GSK's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLAXF vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, GSK's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where GSK's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
GSK (GLAXF) has a 3-Year ROIIC % of 38.82 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #188 out of 941 companies in the Drug Manufacturers industry, placing it in the top 20%.
Is GSK's 3-Year ROIIC % too high?
GSK's current 3-Year ROIIC % is 38.82. The Drug Manufacturers industry median 3-Year ROIIC % is 3.70. GSK's value of 38.82 is 949.2% above this industry median. Based on the distribution chart, GSK ranks #188 out of 941 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #188 out of 941 companies for 3-Year ROIIC %. This places GSK in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.70. GSK's value of 38.82 is 949.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.70, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current 3-Year ROIIC % of 38.82 is 949.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current 3-Year ROIIC % is 38.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.09, compared to a current price of $25.33 — trading 20.1% above its estimated fair value. The current 3-Year ROIIC % is 38.82 and 949.2% above the Drug Manufacturers industry median of 3.70. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For GSK (GLAXF), the current 3-Year ROIIC % is 38.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.33 is trading 20.1% above its estimated GF Value™ of $21.09.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
3-Year ROIIC %: 38.82
GF Value™: $21.09 vs. price of $25.33 (20.1% above fair value)
Industry Position: 949.2% above the Drug Manufacturers median (#188 of 941)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
